ASX:NEU - Trofinetide US patent protections extended to March 2041

Neuren Pharmaceuticals

ABOUT US

Company Overview Company Values Board of Directors Executive Management Corporate Governance Corporate Directory Recruitment

PRODUCTS

DAYBUE® (trofinetide)

PIPELINE

Pipeline Phelan-McDermid Syndrome Pitt Hopkins Syndrome Hypoxic-ischemic encephalopathy Other Programs Compassionate Use

SCIENCE

Our Science Scientific Publications and Presentations

INVESTORS

Investor Dashboard ASX Announcements Annual and Interim Reports Investor Presentations Share Price Information Analyst Coverage Dividends

Trofinetide US patent protections extended to March 2041

Your question will be sent privately to Neuren Pharmaceuticals. The company may choose to make this question public.

Start the conversation

Ask Neuren Pharmaceuticals a question about this announcement.

Share your feedback

Discover